Overcoming market access hurdles will be a challenge for a newly approved drug for major depressive disorder, Auvelity. But, a favorable efficacy and adverse event profile will likely help to facilitate patient access.
The first installment in a series that will explain a recent and revolutionary cell therapy called CAR T, delving into current successes and future opportunities.
A new study from the Medical College of Georgia at Augusta University has found that irrigating your nose twice a day with a saline solution after testing positive for Covid-19 can decrease your chances of hospitalization and death in higher-risk patie…
Recent discoveries in Alzheimer’s disease research have thrown into question fundamental assumptions about the disease and its origins. In the second installment of this series, we introduce the primary risk factor of Alzheimer’s and how it may cause c…
Like influenza, SARS-CoV-2 is an expert at mutating and evading prior immunity. This includes vaccine-induced immunity. New research suggests that expanding the target area of our vaccines to include the virus’ nucleocapsid protein may offer stronger a…
If deemed to meet the reasonable and necessary criteria, Medicare may – for lecanemab – remove the conditional access barrier it imposed on all beta amyloid-directed monoclonal antibodies in the National Coverage Determination (NCD) issued in April of …
Perhaps lessons can be learned on how to cope with the current Ugandan crisis from a British obstetrician’s account of what it was like to be a doctor on the front lines of an unfolding Ebola epidemic in Sierra Leone in 2014 while struggling to save th…
Flu vaccines need to be readministered every year to keep pace with viral mutations. “Universal vaccines” could change this. Here, we describe a recent success in the development of a universal influenza A vaccine.